Stay updated with breaking news from Cell Therapy Engineering Facility. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Buffalo, NY (PRWEB) September 28, 2022 -- A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study published today by the New England Journal of Medicine.